Home › Products › Oncology › Jemperli Injection
Jemperli Injection
Salt Composition: DOSTARLIMAB
- Manufacturer: GLAXO SMITHKLINE PHARMACEUTICALS LTD
- Pack Size: 1 VIAL(s) OF 10ML
- Dosage Form: INJECTION
- Strength: 500MG
- Prescription Required
- Cold Chain
- Prepaid Only. Non-Returnable.
- Storage: Jemperli Injection is stored in hospitals/clinics at 2–8°C (refrigerated). Protect from light and freezing. Infusion should only be prepared and administered by healthcare professionals.
₹332088.00₹390691.88
Inclusive of all taxes
Product Introduction
Jemperli Injection is a prescription medicine used in the treatment of certain advanced or recurrent cancers. It belongs to the class of immune checkpoint inhibitors that target the programmed death receptor-1 (PD-1) pathway. By blocking PD-1, Jemperli Injection restores the ability of the immune system to detect and attack cancer cells. It is administered as an intravenous infusion, typically every 3–6 weeks, under medical supervision. Jemperli Injection has demonstrated particular benefit in patients with mismatch repair-deficient (dMMR) or microsatellite instability-high (MSI-H) tumours, which depend on faulty DNA repair mechanisms. Regular monitoring of liver function, thyroid levels, and immune-related side effects is necessary. As an immunotherapy, it may cause the immune system to attack healthy tissues (immune-related adverse events). It should not be used during pregnancy or breastfeeding, and patients with autoimmune conditions or organ transplants must inform their doctor before commencing therapy.
Uses
Treatment of adult patients with recurrent or advanced dMMR/MSI-H endometrial cancer that has progressed on or after prior therapy and who are not candidates for curative surgery or radiation. Treatment of adult patients with dMMR/MSI-H recurrent or advanced solid tumours (including colorectal cancer) that have progressed on or after prior treatment and have no satisfactory alternative options. Investigated in clinical trials for ovarian cancer, endometrial cancer (first-line), and other advanced solid tumours.
How it works
Cancer cells can evade immune detection by activating the PD-1 receptor on T-cells, which shuts down the immune attack. Jemperli Injection is a PD-1 blocking antibody that prevents this “off switch” from being triggered. By blocking PD-1, Jemperli Injection allows T-cells to remain active, enabling the immune system to recognise and destroy cancer cells more effectively. This results in long-lasting antitumor responses in many patients with dMMR/MSI-H cancers.
Side Effects
Serious (immune-related): Pneumonitis (lung inflammation: cough, chest pain, shortness of breath) Hepatitis (jaundice, dark urine, abdominal pain) Colitis (diarrhoea, bloody stools, abdominal pain) Endocrinopathies (thyroid, pituitary, adrenal problems causing fatigue, weight change, mood changes) Severe skin reactions (rash, blistering, peeling) Infusion reactions (fever, chills, dizziness, shortness of breath) Common: Fatigue Nausea Diarrhoea or constipation Loss of appetite Anemia Cough Rash or itching Muscle/joint pain
References
- David O’Malley et al., “Checkpoint inhibition in mismatch repair-deficient tumors: Jemperli Injection outcomes,” The Lancet Oncology, [2022] https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(22)00299-4/fulltext
- U.S. FDA, “FDA grants accelerated approval to Jemperli Injection -gxly for dMMR endometrial cancer,” [April 2021] https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-Jemperli Injection -gxly-dmmr-endometrial-cancer
- EMA, “Jemperli (Jemperli Injection ): EPAR – Product Information,” [Accessed Sept 2025] https://www.ema.europa.eu/en/medicines/human/EPAR/jemperli
- Luis A. Diaz Jr. et al., “Mismatch Repair Deficiency and Response to PD-1 Blockade in Colorectal Cancer,” The New England Journal of Medicine, [2022] https://www.nejm.org/doi/full/10.1056/NEJMoa2201445
Safety Advice
Pregnancy: Unsafe It is recommended to avoid Jemperli Injection during pregnancy, as it may harm the developing fetus. If you are pregnant, planning to become pregnant, or suspect pregnancy, consult your doctor before starting treatment. The doctor will assess the potential risks and benefits.
Lungs: Consult Your Doctor Immune checkpoint inhibitors like Jemperli Injection may cause inflammation in the lungs (pneumonitis). Consult your doctor if you have a history of lung disease or experience breathing difficulties before starting this treatment.
Breastfeeding: Consult Your Doctor It is unknown whether Jemperli Injection passes into breast milk. Consult your doctor before taking this medicine while breastfeeding. The doctor may prescribe it only if the expected benefits outweigh the potential risks.
Disclaimer
The information provided on this page is intended for general informational purposes only and should not be considered as medical advice. Always consult a qualified healthcare professional before starting, stopping, or changing any medication. Self-medication can be harmful. Med For Rare does not endorse self-diagnosis or self-treatment.